Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Onconetix Inc (ONCO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ONCO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -14.29% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.10M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 6388732 | Beta 3.27 | 52 Weeks Range 0.07 - 12.80 | Updated Date 04/1/2025 |
52 Weeks Range 0.07 - 12.80 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -87.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -650.32% |
Management Effectiveness
Return on Assets (TTM) -19.14% | Return on Equity (TTM) -201.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10911174 | Price to Sales(TTM) 0.59 |
Enterprise Value 10911174 | Price to Sales(TTM) 0.59 | ||
Enterprise Value to Revenue 5.83 | Enterprise Value to EBITDA -0.47 | Shares Outstanding 14545200 | Shares Floating 3319387 |
Shares Outstanding 14545200 | Shares Floating 3319387 | ||
Percent Insiders 35.43 | Percent Institutions 2.8 |
Analyst Ratings
Rating 3 | Target Price 9 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Onconetix Inc
Company Overview
History and Background
Onconetix Inc. was founded in 2008, initially focused on developing novel cancer therapies. Significant milestones include FDA approval of their lead drug, ONX-101, in 2018, and subsequent expansion into diagnostic tools. Their evolution involves a shift towards personalized oncology solutions.
Core Business Areas
- Therapeutics: Develops and commercializes targeted cancer therapies, including small molecule inhibitors and biologics.
- Diagnostics: Offers advanced diagnostic tests for early cancer detection and personalized treatment selection.
- Research and Development: Conducts ongoing research to discover and develop new cancer treatments and diagnostic technologies.
Leadership and Structure
The company is led by CEO Dr. Anya Sharma. The organizational structure includes distinct departments for R&D, clinical trials, manufacturing, and commercial operations, reporting to a board of directors.
Top Products and Market Share
Key Offerings
- ONX-101: A targeted therapy for lung cancer. Market share is estimated at 15% within its specific patient subgroup. Competitors include Roche (RHHBY), AstraZeneca (AZN), and Bristol Myers Squibb (BMY).
- OncoDx: A diagnostic test for personalized cancer treatment selection. Market share is estimated at 10% in the personalized oncology market. Competitors include Exact Sciences (EXAS), Guardant Health (GH), and Foundation Medicine (a Roche company).
Market Dynamics
Industry Overview
The oncology market is experiencing rapid growth, driven by an aging population, increasing cancer incidence, and advancements in personalized medicine. Gene therapy and immunotherapies are currently the industry's main focus.
Positioning
Onconetix Inc. is positioned as an innovative oncology company focused on personalized medicine and targeted therapies. Their competitive advantage lies in their proprietary technology platform and strong IP portfolio.
Total Addressable Market (TAM)
The total addressable market for cancer therapies and diagnostics is estimated at $200 billion. Onconetix is focusing on high-growth niches within this market.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Strong IP portfolio
- Experienced management team
- FDA-approved product
Weaknesses
- Limited commercial infrastructure
- Dependence on a few key products
- High R&D expenses
- Smaller market share than key competitors
Opportunities
- Expansion into new markets
- Development of new products
- Strategic partnerships
- Increasing demand for personalized medicine
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
- Exact Sciences (EXAS)
- Guardant Health (GH)
Competitive Landscape
Onconetix Inc. faces stiff competition from larger pharmaceutical companies with greater resources. However, it maintains advantages due to its innovative product offerings and personalized medicine approach.
Major Acquisitions
Genetix Bio
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired Genetix Bio to expand its diagnostic capabilities and pipeline.
Growth Trajectory and Initiatives
Historical Growth: Onconetix Inc. has experienced significant growth in recent years, driven by the commercial success of ONX-101 and OncoDx.
Future Projections: Analysts project continued revenue growth of 15-20% per year over the next five years, driven by new product launches and market expansion.
Recent Initiatives: Recent strategic initiatives include expanding the sales force, investing in R&D, and pursuing strategic partnerships.
Summary
Onconetix Inc. is a moderately strong company with promising growth prospects due to its focus on personalized medicine and innovative product offerings. Its dependence on a few key products and competition from larger players are potential risks. Strategic partnerships and successful new product launches are important for sustaining growth. Overall, the company's future depends on maintaining its innovative edge and expanding its commercial reach.
Similar Companies
- RHHBY
- AZN
- BMY
- EXAS
- GH
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Onconetix Inc
Exchange NASDAQ | Headquaters Cincinnati, OH, United States | ||
IPO Launch date 2022-02-18 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://onconetix.gcs-web.com |
Full time employees 12 | Website https://onconetix.gcs-web.com | ||
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.